Biotechnology company Amyris announced on Thursday that it has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for USD12.3m from the Administration for Strategic Preparedness and Response's (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC).
The company has received the agreement to advance innovative pharmaceutical manufacturing in the United States.
Amyris says that it intends to develop up to three molecule drugs over the next two years, all of which are on the FDA drug shortage list utilising its advanced technology in organism engineering, advanced precision fermentation, synthetic chemistry, process expertise and manufacturing.
IBMSC and Amyris will jointly decide which drug targets to advance to sample production. During the agreement term, Amyris will explore partnerships with GMP-manufacturing capabilities and market access to bring fully developed drugs to market.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval